Resident Exam Performance Similar Regardless of Remote, In-Person Proctoring
By Lori Solomon HealthDay Reporter
WEDNESDAY, March 6, 2024 -- Performance on the 2020 Internal Medicine In-Training Examination did not substantively differ across in-person and remote examinees, according to a study published online Jan. 29 in Academic Medicine.
Thai Q. Ong, Ph.D., from the National Board of Medical Examiners in Philadelphia, and colleagues evaluated the extent to which scores obtained from both testing modalities (in-person and remote proctoring) were comparable. The analysis included 27,115 residents completing the 2020 Internal Medicine In-Training Examination.
The researchers found that 42 percent tested remotely and 58 percent in person. The only statistically significant effects were the interaction between testing mode (interaction effect, −0.61) and postgraduate year (PGY; interaction effect, −0.54). For PGY-1, the differences between in-person and remote predicted scores were slightly larger compared with PGY-2 and PGY-3 residents, when controlling for the other predictors. However, the magnitude of these differences across residency training was well under a single percentage point. These statistically significant effects were deemed educationally nonsignificant.
"Residency programs choose remotely proctored testing to accommodate a myriad of scheduling challenges, and they should be reassured that they can continue to enjoy the flexibility of this self-assessment testing modality, with results comparable to in-person testing results," study coauthor Margaret Wells, also from the National Board of Medical Examiners, said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.